First, GEP analyses revealed that tumour cells from MM patients express higher levels of TCF3 than normal plasma cells, and that TCF3 expression correlates with disease progression in MM (GSE6477, GSE39754) (Supplementary Fig. S7A and B). This evidence concerns the gene TCF3 and Miyoshi myopathy.